BBLG Stock Chart & Stats
$1.39
-$0.09(-8.18%)
At close: 4:00 PM EST
$1.39
-$0.09(-8.18%)
Day’s Range― - ―
52-Week Range$1.05 - $4.13
Previous Close$1.03
Volume215.57K
Average Volume (3M)155.76K
Market Cap
$2.41M
Enterprise Value-$1.89M
Total Cash (Recent Filing)$4.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding1,795,260
10 Day Avg. Volume84,635
30 Day Avg. Volume155,764
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.32
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap-0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.93
Revenue Forecast (FY)N/A
Bone Biologics News
BBLG FAQ
What was Bone Biologics Corp.’s price range in the past 12 months?
Bone Biologics Corp. lowest stock price was $1.05 and its highest was $4.13 in the past 12 months.
What is Bone Biologics Corp.’s market cap?
Bone Biologics Corp.’s market cap is $2.41M.
When is Bone Biologics Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bone Biologics Corp.’s earnings last quarter?
Currently, no data Available
Is Bone Biologics Corp. overvalued?
According to Wall Street analysts Bone Biologics Corp.’s price is currently Overvalued.
Does Bone Biologics Corp. pay dividends?
Bone Biologics Corp. does not currently pay dividends.
What is Bone Biologics Corp.’s EPS estimate?
Bone Biologics Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bone Biologics Corp. have?
Bone Biologics Corp. has 1,795,260 shares outstanding.
What happened to Bone Biologics Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bone Biologics Corp.?
Currently, no hedge funds are holding shares in BBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bone Biologics Corp.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Technical Analysis
Ownership Overview
0.04%
Insiders
0.44% Mutual Funds
1.31% Other Institutional Investors
98.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---